Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Alexion Pharmaceuticals, Inc.
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
July 15, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
June 11, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 07, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021
May 12, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress
May 12, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
Alexion Reports First Quarter 2021 Results
April 30, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021
April 28, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021
April 20, 2021
From
Alexion Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.